Vantive launches in Việt Nam as standalone kidney care leader

October 11, 2025 - 18:00
Vantive, formerly the Baxter Kidney Care segment, announced its official launch in Việt Nam as a new standalone vital therapy company.
Country Head of Vantive Vietnam Trần Thùy Dương speaks at the official launch event of Vantive Vietnam Healthcare on October 11 — Photo Vantive

HÀ NỘI — Vantive, formerly the Baxter Kidney Care segment, announced its official launch in Việt Nam as a new standalone vital therapy company.

Speaking at the official launch event of Vantive Vietnam Healthcare on October 11, Country Head of Vantive Vietnam Trần Thùy Dương said that Vantive is tackling kidney disease on multiple fronts, including providing advanced treatment options, investing in innovation and digital solutions for better management, supporting healthcare professional training programmes through partnerships, and bringing global expertise to support Việt Nam’s healthcare.

Building on 70 years of legacy in dialysis and organ support therapies, Vantive remains focused with a clear mission to extend lives and expand possibilities for patients with kidney disease as well as healthcare professionals.

As a standalone company in Việt Nam, Vantive can concentrate solely on vital organ therapies, including kidney care. This sharpened structure strengthens the company’s commitment and enables more targeted investment and innovation, ultimately bringing more advanced, specialised solutions to patients and healthcare professionals in Việt Nam.

Kidney disease remains a heavy burden on the people and the healthcare system. Around 10 million Vietnamese adults—that’s nearly 10 per cent of the population—are living with chronic kidney disease (CKD), yet many are diagnosed only at advanced stages, and only five per cent of end-stage have access to timely treatment.

Acute kidney injury (AKI) further compounds the challenge. Critically ill patients in intensive care units (ICU) often develop AKI as a complication of sepsis, trauma, or surgery.

For critically ill patients, AKI adds another layer of complexity, with more than 40 per cent of ICU patients needing renal replacement therapy treated via Continuous Renal Replacement Therapy, intensifying the workload on already stretched intensive care units.

Vantive remains committed to driving innovation that improves patient outcomes, with solutions designed to meet the specific needs of Việt Nam’s healthcare system. Through ongoing research and development, and through digital solutions that enable smarter, more efficient care, the company is building therapies that ensure advanced kidney care is within reach for all. — VNS

E-paper